115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed / refractory marginal zone lymphoma: Results from phase 1/2 BRUIN study
    Meeting Abstract

    Patel, K.; Vose, J. M.; Nasta, S. D.; Brown, J. R.; Maddocks, K. J.; Woyach, J. A.; Shah, N. N.; Fakhri, B.; Tessoulin, B.; Ma, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pelabresib in combination with ruxolitinib for Janus Kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study
    Meeting Abstract

    Rampal, R. K.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Invasive fungal infections after CAR T-cell therapy for B-cell lymphoma: A study from the French DESCART registry
    Meeting Abstract

    Bouvier, A.; Durand, A.; Gower, N.; Castilla-Llorente, C.; Campidelli, A.; Dulery, R.; Gangneux, J. P.; Joris, M.; Eloit, M.; Fayard, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma
    Meeting Abstract

    Morschhauser, F.; Dahiya, S.; Palomba, M. L.; Garcia-Sancho, A. M.; Reguera, J. L.; Kuruvilla, J.; Jaeger, U.; Cartron, G.; Izutsu, K.; Dreyling, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The composite health risk assessment model (CHARM) to predict 1-year non-relapse mortality (NRM) among older recipients of allogeneic transplantation: A prospective BMT-CTN study 1704
    Meeting Abstract

    Artz, A.; Logan, B. R.; Saber, W.; Geller, N.; Bellach, A.; Kou, J.; Wood, W.; McCarty, J. M.; Knight, T. G.; Runaas, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Improved overall survival with axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma among the elderly: A subgroup analysis of ZUMA-7
    Meeting Abstract

    Kersten, M. J.; Farooq, U.; Rapoport, A. P.; Locke, F. L.; Leslie, L. A.; Ghobadi, A.; Miklos, D. B.; Jacobson, C. A.; Munoz, J. L.; Johnston, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Treatment patterns and outcomes for patients with classic Hodgkin lymphoma (cHL) and cardiomyopathy with low ejection fraction (EF): Real-world evidence (RWE) from 16 US academic centers
    Meeting Abstract

    Annunzio, K.; McLaughlin, E.; Voorhees, T.; Shea, L. K.; Sumransub, N.; Rose, A.; Olszewski, A. J.; Bailey, N.; Patel, K.; Moyo, T. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3
    Meeting Abstract

    Otero, P. R.; Ailawadhi, S.; Arnulf, B.; Patel, K. K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N. S.; Costa, L.; Vij, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A
    Meeting Abstract

    Brierley, C. K.; Yip, B. H.; Orlando, G.; Goyal, H.; Wen, S.; Wen, J.; Levine, M. F.; Rodriguez-Meira, A.; Adamo, A.; Bashton, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Molecular taxonomy of myelodysplastic syndromes and its clinical implications
    Meeting Abstract

    Bernard, E.; Hasserjian, R.; Greenberg, P. L.; Ossa, J. E. A.; Creignou, M.; Nannya, Y.; Tuechler, H.; Medina-Martínez, J. S.; Levine, M. F.; Jädersten, M.; more...
    Blood (2023)

    Fulltext@MSK | Save